Cargando…
De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
Canagliflozin is a sodium-glucose co-transporter 2 inhibitor that reduces glycemia as well as the risk of cardiovascular events. Our main objective was to analyze antidiabetic treatment de-intensification and the glycemic efficacy of replacing antidiabetic agents (excluding metformin) with canaglifl...
Autores principales: | Pérez-Belmonte, Luis M., Ricci, Michele, Sanz-Cánovas, Jaime, Cobos-Palacios, Lidia, López-Carmona, María D., Ruiz-Moreno, M. Isabel, Millán-Gómez, Mercedes, Bernal-López, M. Rosa, Jansen-Chaparro, Sergio, Gómez-Huelgas, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125841/ https://www.ncbi.nlm.nih.gov/pubmed/34066707 http://dx.doi.org/10.3390/jcm10092013 |
Ejemplares similares
-
Statins and Peripheral Arterial Disease: A Narrative Review
por: Jansen-Chaparro, Sergio, et al.
Publicado: (2021) -
Statin Therapy in Very Old Patients: Lights and Shadows
por: Cobos-Palacios, Lidia, et al.
Publicado: (2021) -
Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia
por: Sanz-Cánovas, Jaime, et al.
Publicado: (2022) -
Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021) -
Remission of type 2 diabetes: A critical appraisal
por: Ricci, Michele, et al.
Publicado: (2023)